Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07276074

Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals

Sponsor: University Hospital, Strasbourg, France

View on ClinicalTrials.gov

Summary

Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially low-molecular-weight heparin (LMWH). In intensive care, patients are mostly treated with anticoagulants for either preventive or curative purposes, particularly for those whose care requires renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), or cardiopulmonary bypass (CPB). The use of various types of membranes associated with these procedures can lead to degradation of blood proteins (including AT). An imbalance in hemostasis can then occur, resulting in ineffective anticoagulation. At the Strasbourg University Hospitals (HUS), these medications are directly available in the intensive care units, allowing for immediate administration in an emergency. Pharmaceutical and medical analysis is therefore not performed before administration.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

160

Start Date

2024-12-18

Completion Date

2025-12-31

Last Updated

2025-12-10

Healthy Volunteers

No

Locations (1)

Service d'Anesthésie et Réanimation chirurgicale - CHU de Strasbourg - France

Strasbourg, France